JP2016532693A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016532693A5 JP2016532693A5 JP2016532265A JP2016532265A JP2016532693A5 JP 2016532693 A5 JP2016532693 A5 JP 2016532693A5 JP 2016532265 A JP2016532265 A JP 2016532265A JP 2016532265 A JP2016532265 A JP 2016532265A JP 2016532693 A5 JP2016532693 A5 JP 2016532693A5
- Authority
- JP
- Japan
- Prior art keywords
- immunocytokine
- amino acid
- antibody
- acid sequence
- antagonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940127130 immunocytokine Drugs 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 239000005557 antagonist Substances 0.000 claims 9
- 230000002519 immonomodulatory effect Effects 0.000 claims 5
- 230000001506 immunosuppresive effect Effects 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 102000003812 Interleukin-15 Human genes 0.000 claims 3
- 108090000172 Interleukin-15 Proteins 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 102000056003 human IL15 Human genes 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102100035990 Adenosine receptor A2a Human genes 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 229940122786 CD134 agonist Drugs 0.000 claims 1
- 229940116741 CD137 agonist Drugs 0.000 claims 1
- 229940123189 CD40 agonist Drugs 0.000 claims 1
- 102000007346 Hepatitis A Virus Cellular Receptor 2 Human genes 0.000 claims 1
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 claims 1
- 101000783751 Homo sapiens Adenosine receptor A2a Proteins 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229940124060 PD-1 antagonist Drugs 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 108091008034 costimulatory receptors Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000004957 immunoregulator effect Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020004814A JP6951479B2 (ja) | 2013-08-08 | 2020-01-16 | ＩＬ−１５及びＩＬ−１５Ｒαスシドメインに基づくモジュロカイン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13003963 | 2013-08-08 | ||
| EP13003963.9 | 2013-08-08 | ||
| PCT/EP2014/002181 WO2015018528A1 (en) | 2013-08-08 | 2014-08-08 | Il-15 and il-15raplha sushi domain based modulokines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020004814A Division JP6951479B2 (ja) | 2013-08-08 | 2020-01-16 | ＩＬ−１５及びＩＬ−１５Ｒαスシドメインに基づくモジュロカイン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016532693A JP2016532693A (ja) | 2016-10-20 |
| JP2016532693A5 true JP2016532693A5 (enExample) | 2017-09-14 |
| JP6649254B2 JP6649254B2 (ja) | 2020-02-19 |
Family
ID=48953308
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016532265A Active JP6649254B2 (ja) | 2013-08-08 | 2014-08-08 | ＩＬ−１５及びＩＬ−１５Ｒαスシドメインに基づくモジュロカイン |
| JP2020004814A Active JP6951479B2 (ja) | 2013-08-08 | 2020-01-16 | ＩＬ−１５及びＩＬ−１５Ｒαスシドメインに基づくモジュロカイン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020004814A Active JP6951479B2 (ja) | 2013-08-08 | 2020-01-16 | ＩＬ−１５及びＩＬ−１５Ｒαスシドメインに基づくモジュロカイン |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11273204B2 (enExample) |
| EP (4) | EP3995507B1 (enExample) |
| JP (2) | JP6649254B2 (enExample) |
| KR (2) | KR102564207B1 (enExample) |
| CN (1) | CN105612175B (enExample) |
| AU (1) | AU2014304931B2 (enExample) |
| BR (1) | BR112016002614B8 (enExample) |
| CA (1) | CA2919725C (enExample) |
| DK (2) | DK3444271T3 (enExample) |
| EA (1) | EA031080B1 (enExample) |
| ES (3) | ES2902589T3 (enExample) |
| HR (3) | HRP20212023T1 (enExample) |
| HU (2) | HUE057598T2 (enExample) |
| MX (1) | MX374291B (enExample) |
| PL (3) | PL3995507T3 (enExample) |
| PT (2) | PT3030575T (enExample) |
| SI (2) | SI3444271T1 (enExample) |
| WO (1) | WO2015018528A1 (enExample) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI531652B (zh) | 2005-12-02 | 2016-05-01 | 美國紐約大學西奈山醫學院 | 表現非原生表面蛋白質之嵌合病毒及其用途 |
| EP2537933A1 (en) * | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| CA2898100C (en) | 2013-01-14 | 2023-10-10 | Xencor, Inc. | Novel heterodimeric proteins |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| NZ711946A (en) | 2013-03-14 | 2020-05-29 | Icahn School Med Mount Sinai | Newcastle disease viruses and uses thereof |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| EP3421495A3 (en) | 2013-03-15 | 2019-05-15 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| EP4032540A1 (en) * | 2013-04-19 | 2022-07-27 | Cytune Pharma | Cytokine derived treatment with reduced vascular leak syndrome |
| CA2940570A1 (en) | 2014-02-27 | 2015-09-03 | Viralytics Limited | Combination method for treatment of cancer |
| EP2915569A1 (en) | 2014-03-03 | 2015-09-09 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| CN114081946A (zh) | 2014-03-12 | 2022-02-25 | 耶达研究与开发有限公司 | 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤 |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
| MX385936B (es) | 2014-03-28 | 2025-03-11 | Xencor Inc | Anticuerpos biespecíficos que se unen a cd38 y cd3. |
| HRP20211273T1 (hr) | 2014-11-26 | 2021-11-12 | Xencor, Inc. | Heterodimerna protutijela koja vežu cd3 i cd20 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| MX2017006918A (es) | 2014-11-26 | 2018-01-25 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y cd38. |
| EP3237449A2 (en) | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Trispecific antibodies |
| WO2016141387A1 (en) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| US20180155439A1 (en) * | 2015-06-10 | 2018-06-07 | Emory University | Compositions and Conjugates Comprising an Interleukin and Polypeptides That Specifically Bind TGF-beta |
| JP6800219B2 (ja) * | 2015-09-16 | 2020-12-16 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 特異的なインターロイキン−１５（ｉｌ−１５）アンタゴニストポリペプチド並びに炎症疾患及び自己免疫疾患の処置のためのその使用 |
| CN114773481B (zh) | 2015-10-02 | 2025-04-29 | 豪夫迈·罗氏有限公司 | 对pd1和tim3特异性的双特异性抗体 |
| JP7058219B2 (ja) | 2015-12-07 | 2022-04-21 | ゼンコア インコーポレイテッド | Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体 |
| US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| EP3411065B1 (en) * | 2016-02-05 | 2021-03-31 | Orionis Biosciences BV | Clec9a binding agents |
| CA3017813C (en) * | 2016-03-17 | 2021-12-07 | Oslo Universitetssykehus Hf | Fusion proteins targeting tumour associated macrophages for treating cancer |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| MA45037A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polythérapie à base d'arnm pour le traitement du cancer |
| US11472856B2 (en) | 2016-06-13 | 2022-10-18 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
| FI3468586T3 (fi) | 2016-06-14 | 2024-10-29 | Xencor Inc | Bispesifisiä immuuniaktivaatiota vapauttavia vasta-aineita |
| EP3475304B1 (en) | 2016-06-28 | 2022-03-23 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| CA3040504A1 (en) * | 2016-10-14 | 2018-04-19 | Xencor, Inc. | Il15/il15ra heterodimeric fc-fusion proteins |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| RU2761377C2 (ru) * | 2017-04-03 | 2021-12-07 | Ф. Хоффманн-Ля Рош Аг | Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15 |
| FI3606955T3 (fi) | 2017-04-05 | 2025-01-08 | Hoffmann La Roche | Pd1:een ja lag3:een spesifisesti sitoutuvia bispesifisiä vasta-aineita |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| MA49517A (fr) | 2017-06-30 | 2020-05-06 | Xencor Inc | Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène |
| JP7423511B2 (ja) | 2017-08-09 | 2024-01-29 | オリオンズ バイオサイエンス インコーポレイテッド | Ｐｄ－１およびｐｄ－ｌ１結合物質 |
| CA3069930A1 (en) | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | Cd8 binding agents |
| SG11202001063QA (en) | 2017-08-09 | 2020-03-30 | Orionis Biosciences Inc | Clec9a binding agents and use thereof |
| JP7285828B2 (ja) | 2017-09-05 | 2023-06-02 | トルク セラピューティクス， インコーポレイテッド | 治療用タンパク質組成物ならびにその作製および使用方法 |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| WO2019094637A1 (en) | 2017-11-08 | 2019-05-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
| KR102722731B1 (ko) | 2017-12-19 | 2024-10-25 | 젠코어 인코포레이티드 | 조작된 il-2 fc 융합 단백질 |
| TW201938196A (zh) * | 2018-01-18 | 2019-10-01 | 美商南特生物科學股份有限公司 | 融合蛋白擴展 |
| MX387358B (es) | 2018-02-28 | 2025-03-18 | Pfizer | Variantes de il-15 y usos de las mismas |
| CN112469477A (zh) | 2018-04-04 | 2021-03-09 | Xencor股份有限公司 | 与成纤维细胞活化蛋白结合的异源二聚体抗体 |
| JP2021521784A (ja) * | 2018-04-18 | 2021-08-30 | ゼンコア インコーポレイテッド | ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用 |
| IL310398A (en) | 2018-04-18 | 2024-03-01 | Xencor Inc | Proteins from heterodimeric il-15/il-15rα fc and their uses |
| EP3781597A1 (en) * | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains |
| CA3097741A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
| WO2020037215A1 (en) | 2018-08-17 | 2020-02-20 | Icahn School Of Medicine At Mount Sinai | Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease |
| SG11202103192RA (en) | 2018-10-03 | 2021-04-29 | Xencor Inc | Il-12 heterodimeric fc-fusion proteins |
| CA3116188A1 (en) | 2018-10-12 | 2020-04-16 | Xencor, Inc. | Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof |
| US12410225B2 (en) | 2018-11-08 | 2025-09-09 | Orionis Biosciences, Inc | Modulation of dendritic cell lineages |
| US11618776B2 (en) | 2018-12-20 | 2023-04-04 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains |
| MX2021010390A (es) | 2019-03-01 | 2021-11-17 | Xencor Inc | Anticuerpos heterodimericos que se unen a enpp3 y cd3. |
| JP7773371B2 (ja) | 2019-03-28 | 2025-11-19 | オリオニス バイオサイエンシズ，インコーポレイテッド | Ｃｌｅｃ９ａベースキメラタンパク質複合体 |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| KR20220012296A (ko) | 2019-05-20 | 2022-02-03 | 싸이튠 파마 | 암 또는 감염성 질환 치료를 위한 IL-2/IL-15Rβγ 작용제 투여 요법 |
| MX2022002024A (es) * | 2019-08-17 | 2022-03-11 | Igm Biosciences Inc | Moleculas de union anti-cd123 multimericas biespecificas y usos de estas. |
| CN110478474B (zh) * | 2019-08-21 | 2020-06-02 | 启辰生生物科技(珠海)有限公司 | 免疫调节剂、疫苗、细胞及应用 |
| CN116574183A (zh) * | 2019-08-22 | 2023-08-11 | 盛禾(中国)生物制药有限公司 | 多功能抗体、其制备及其用途 |
| EP4028413A1 (en) | 2019-09-10 | 2022-07-20 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
| RU2753282C2 (ru) | 2019-09-19 | 2021-08-12 | Закрытое Акционерное Общество "Биокад" | ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| JP2023502712A (ja) * | 2019-11-21 | 2023-01-25 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | 抗ｐｄ－１／ｉｌ－１５免疫サイトカインによる新しいｐｄ－１標的免疫療法 |
| CN110804588B (zh) * | 2019-11-22 | 2020-09-01 | 启辰生生物科技(珠海)有限公司 | 用于协同改善t淋巴细胞性质的组合物及其应用 |
| WO2021113577A1 (en) * | 2019-12-05 | 2021-06-10 | Immune Targeting Inc. | Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof |
| EP3889183A1 (en) * | 2020-04-01 | 2021-10-06 | Pierre Fabre Medicament | A protein complex comprising an immunocytokine |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| WO2022040482A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| CN116134140A (zh) * | 2020-09-01 | 2023-05-16 | 上海药明生物技术有限公司 | 长效作用的il-15及其用途 |
| JP2023550685A (ja) | 2020-10-26 | 2023-12-05 | サイチューン ファーマ | 扁平上皮癌を治療するためのＩＬ－２／ＩＬ－１５Ｒβγアゴニスト |
| WO2022090202A1 (en) | 2020-10-26 | 2022-05-05 | Cytune Pharma | IL-2/IL-15RBβү AGONIST FOR TREATING NON-MELANOMA SKIN CANCER |
| CN117157319A (zh) | 2021-03-09 | 2023-12-01 | Xencor股份有限公司 | 结合cd3和cldn6的异二聚抗体 |
| KR20230154311A (ko) | 2021-03-10 | 2023-11-07 | 젠코어 인코포레이티드 | Cd3 및 gpc3에 결합하는 이종이량체 항체 |
| US20230151095A1 (en) | 2021-11-12 | 2023-05-18 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
| CA3238283A1 (en) * | 2021-11-15 | 2023-05-19 | Yangxin Fu | Fusion protein construct taking interleukin 15 as active ingredient and use thereof |
| WO2024102636A1 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and mica/b |
| WO2025085672A1 (en) | 2023-10-17 | 2025-04-24 | Xencor, Inc. | Bispecific antibodies that bind to nkp46 and mica/b |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5997856A (en) | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5108910A (en) | 1989-08-22 | 1992-04-28 | Immunex Corporation | DNA sequences encoding fusion proteins comprising GM-CSF and IL-3 |
| US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| AU6703198A (en) | 1997-03-21 | 1998-10-20 | Brigham And Women's Hospital | Immunotherapeutic ctla-4 binding peptides |
| SI2112166T1 (sl) | 1998-12-23 | 2019-05-31 | Pfizer Inc. | Človeška monoklonska protitelesa proti CTLA-4 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| CN1371416B (zh) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
| IL149701A0 (en) | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| PL375144A1 (en) | 2002-07-30 | 2005-11-28 | Bristol-Myers Squibb Company | Humanized antibodies against human 4-1bb |
| KR100932340B1 (ko) | 2002-10-17 | 2009-12-16 | 젠맵 에이/에스 | Ｃｄ20에 대한 인간 모노클로날 항체 |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| US20050136055A1 (en) | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
| DK1707627T3 (da) | 2003-12-25 | 2012-12-17 | Kyowa Hakko Kirin Co Ltd | Antagonistisk anti-CD40-antistofmutant. |
| EP1718670B1 (en) | 2004-02-27 | 2011-07-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Il-15 binding site for il 15-ralpha and specific il-15 mutants having agonist/antagonist activity |
| CN1997670B (zh) | 2004-07-01 | 2014-04-30 | 诺和诺德公司 | 人类抗-kir抗体 |
| EP1819702A1 (en) | 2004-11-29 | 2007-08-22 | Pharmacia & Upjohn Company LLC | Thiazepine oxazolidinones as antibacterial agents |
| EP1866339B8 (en) | 2005-03-25 | 2021-12-01 | GITR, Inc. | Gitr binding molecules and uses therefor |
| EP2418278A3 (en) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| MX2007014474A (es) | 2005-05-17 | 2008-02-07 | Univ Connecticut | Composiciones y metodos para inmunomodulacion en un organismo. |
| KR100694508B1 (ko) | 2005-05-24 | 2007-03-13 | 울산대학교 산학협력단 | Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법 |
| KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| EA200970477A1 (ru) | 2006-11-15 | 2009-12-30 | Медарекс, Инк. | Человеческие моноклональные антитела к btla и способы применения |
| CA2947292C (en) | 2006-12-27 | 2019-07-23 | Emory University | Compositions and methods for the treatment of infections and tumors |
| EP2160401B1 (en) | 2007-05-11 | 2014-09-24 | Altor BioScience Corporation | Fusion molecules and il-15 variants |
| EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| NZ703668A (en) | 2007-06-27 | 2016-07-29 | Us Sec Dep Of Health And Human Services | Complexes of il-15 and il-15ralpha and uses thereof |
| SG186656A1 (en) | 2007-12-14 | 2013-01-30 | Bristol Myers Squibb Co | Binding molecules to the human ox40 receptor |
| CN104548091A (zh) | 2008-02-11 | 2015-04-29 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2009135031A1 (en) | 2008-04-30 | 2009-11-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Substituted il-15 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| US20110159023A1 (en) | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
| EA023148B1 (ru) | 2008-08-25 | 2016-04-29 | Эмплиммьюн, Инк. | Композиции на основе антагонистов pd-1 и их применение |
| WO2010029435A1 (en) | 2008-09-12 | 2010-03-18 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
| CA2736816C (en) | 2008-09-12 | 2018-05-22 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
| HUE030807T2 (en) | 2008-09-26 | 2017-05-29 | Dana Farber Cancer Inst Inc | Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications |
| TWI729512B (zh) | 2008-12-09 | 2021-06-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP2408818A1 (en) | 2009-03-17 | 2012-01-25 | Université de la Méditerranée | Btla antibodies and uses thereof |
| IN2012DN00863A (enExample) | 2009-07-31 | 2015-07-10 | Medarex Inc | |
| EP2464377B1 (en) | 2009-08-14 | 2016-07-27 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Use of il-15 to increase thymic output and to treat lymphopenia |
| CN102574924A (zh) | 2009-09-03 | 2012-07-11 | 先灵公司 | 抗-gitr抗体 |
| CN102892786B (zh) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| EA031849B1 (ru) | 2010-08-23 | 2019-03-29 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Антитела к ox40 и способы их применения |
| CN105017429B (zh) * | 2010-09-21 | 2021-04-06 | 阿尔托生物科学有限公司 | 多聚体il-15可溶性融合分子与其制造与使用方法 |
| CA2805361A1 (en) | 2010-09-29 | 2012-04-05 | Universite De Liege | Combination of an agonistic anti-cd40 monoclonal antibody or a cd40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis |
| GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| KR102031020B1 (ko) | 2011-03-31 | 2019-10-14 | 머크 샤프 앤드 돔 코포레이션 | 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료 |
| US20140178368A1 (en) | 2011-04-19 | 2014-06-26 | Leslie Lynne SHARP | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
| DK2699264T3 (en) | 2011-04-20 | 2018-06-25 | Medimmune Llc | ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1 |
| EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| CA2845810C (en) | 2011-08-23 | 2017-03-28 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| NZ630790A (en) * | 2012-10-24 | 2016-11-25 | Admune Therapeutics Llc | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
| EP4032540A1 (en) | 2013-04-19 | 2022-07-27 | Cytune Pharma | Cytokine derived treatment with reduced vascular leak syndrome |
| US9580504B1 (en) | 2013-11-07 | 2017-02-28 | Curetech Ltd. | Pidilizumab monoclonal antibody therapy following stem cell transplantation |
| HUE057917T2 (hu) | 2014-01-15 | 2022-06-28 | Kadmon Corp Llc | Immunmodulátor szerek |
| EP4359428A2 (en) | 2021-06-23 | 2024-05-01 | Cytune Pharma | Interleukin-15 based immunocytokines |
-
2014
- 2014-08-08 EP EP21200870.0A patent/EP3995507B1/en active Active
- 2014-08-08 CN CN201480052636.9A patent/CN105612175B/zh active Active
- 2014-08-08 PL PL21200870.0T patent/PL3995507T3/pl unknown
- 2014-08-08 DK DK18177685.7T patent/DK3444271T3/da active
- 2014-08-08 AU AU2014304931A patent/AU2014304931B2/en active Active
- 2014-08-08 EP EP23191780.8A patent/EP4269441A3/en active Pending
- 2014-08-08 WO PCT/EP2014/002181 patent/WO2015018528A1/en not_active Ceased
- 2014-08-08 BR BR112016002614A patent/BR112016002614B8/pt active IP Right Grant
- 2014-08-08 SI SI201431932T patent/SI3444271T1/sl unknown
- 2014-08-08 EP EP14761280.8A patent/EP3030575B1/en active Active
- 2014-08-08 ES ES18177685T patent/ES2902589T3/es active Active
- 2014-08-08 PL PL18177685T patent/PL3444271T3/pl unknown
- 2014-08-08 KR KR1020227004968A patent/KR102564207B1/ko active Active
- 2014-08-08 HR HRP20212023TT patent/HRP20212023T1/hr unknown
- 2014-08-08 SI SI201430898T patent/SI3030575T1/sl unknown
- 2014-08-08 ES ES21200870T patent/ES2963591T3/es active Active
- 2014-08-08 JP JP2016532265A patent/JP6649254B2/ja active Active
- 2014-08-08 US US14/910,475 patent/US11273204B2/en active Active
- 2014-08-08 HR HRP20231437TT patent/HRP20231437T1/hr unknown
- 2014-08-08 PT PT14761280T patent/PT3030575T/pt unknown
- 2014-08-08 CA CA2919725A patent/CA2919725C/en active Active
- 2014-08-08 PT PT181776857T patent/PT3444271T/pt unknown
- 2014-08-08 HU HUE18177685A patent/HUE057598T2/hu unknown
- 2014-08-08 KR KR1020167005428A patent/KR102364523B1/ko active Active
- 2014-08-08 HR HRP20181472TT patent/HRP20181472T1/hr unknown
- 2014-08-08 PL PL14761280T patent/PL3030575T3/pl unknown
- 2014-08-08 ES ES14761280.8T patent/ES2690046T3/es active Active
- 2014-08-08 MX MX2016001555A patent/MX374291B/es active IP Right Grant
- 2014-08-08 DK DK14761280.8T patent/DK3030575T3/en active
- 2014-08-08 EP EP18177685.7A patent/EP3444271B1/en active Active
- 2014-08-08 EA EA201690333A patent/EA031080B1/ru unknown
- 2014-08-08 HU HUE21200870A patent/HUE064280T2/hu unknown
-
2020
- 2020-01-16 JP JP2020004814A patent/JP6951479B2/ja active Active
-
2022
- 2022-03-11 US US17/693,132 patent/US20220193199A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016532693A5 (enExample) | ||
| HRP20212023T1 (hr) | Modulokini temeljeni na il-15 i il-15ralpha sushi domeni | |
| JP2016527286A5 (enExample) | ||
| CA2848209C (en) | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage | |
| JP2016501839A5 (enExample) | ||
| EP4282877A3 (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
| WO2014089169A4 (en) | Immunotherapy with binding agents | |
| JP2016539096A5 (enExample) | ||
| PH12019502356A1 (en) | Trem2 antigen binding proteins and uses thereof | |
| JP2017527272A5 (enExample) | ||
| PH12019501241A1 (en) | Novel t cell receptors and immune therapy using the same | |
| NZ713461A (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer | |
| HRP20190799T1 (hr) | Imunocitokini na bazi il-15 i sushi domene il-15r alfa | |
| CA3045233A1 (en) | Novel t cell receptors and immune therapy using the same | |
| WO2016191643A4 (en) | Tigit-binding agents and uses thereof | |
| PH12017501372A1 (en) | Tnfrsf-binding agents and uses thereof | |
| AU2015205530A8 (en) | Multi-specific polypeptide useful for localized tumor immunomodulation | |
| HRP20211538T1 (hr) | Novi bispecifični format pogodan za upotrebu u visokopropusnom skriningu | |
| JP2014040431A5 (enExample) | ||
| FI3303396T3 (fi) | Vasta-aineita ox40:ää vastaan ja niiden käyttöjä | |
| MX2011009810A (es) | Composiciones y metodos para usar proteinas de union multiespecificas que comprenden una combinacion anticuerporeceptor. | |
| JP2013519721A5 (enExample) | ||
| JP2016187356A5 (enExample) | ||
| BR112012018914A2 (pt) | "anticorpo humanizado, proteína de ligação de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, proteína de ligação de anticorpo ou de antígeno, métodos para a produção de uma proteína de ligação de antígeno e para tratar um sujeito afetado por uma doença autoimune ou inflamatória, e, composição farmacêutica." | |
| JP2015525217A5 (enExample) |